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Inflammation plays a critical role in tumorigenesis and can contribute to oncogenic muta-
tions, tumor promotion, and angiogenesis.Tumor-promoting inflammation is driven by many
factors including the presence of the pro-inflammatory cytokines interleukin (IL)-1β and
IL-18. One major source of IL-1β and IL-18 secretion is through the activation of inflam-
masomes. Inflammasomes are multi-protein complexes that upon activation lead to the
processing and secretion of IL-1β and IL-18 mediated by the cysteine protease caspase-1.
Several inflammasomes, including NLRP3, NLRC4, and NLRP6, have been implicated in
tumorigenesis. However, inflammasomes play divergent roles in different types of cancer
reflecting the complexity of inflammation during tumorigenesis. Understanding the role of
inflammasome activation during specific stages of tumorigenesis and also during cancer
immunotherapy will help identify novel therapeutic targets that could improve treatment
strategies for cancer patients. Here we will discuss recent advances in understanding the
mechanism by which NLRs regulate carcinogenesis.
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INTRODUCTION
In order to protect us from infection, the immune system has
employed an arsenal of pattern recognition receptors (PRRs) capa-
ble of recognizing a wide variety of microbial pathogens and
viruses. PRRs are also activated under conditions of cell stress
through the detection of damage associated molecular patterns
(DAMPs) (1, 2). However, it is not well understood if and how the
immune system has evolved to recognize overexpressed or mutated
self-antigens in the context of cancer. Various PRRs have been
implicated in cancer, either employing a protective or detrimental
role. However, it remains unknown what causes the activation or
suppression of PRRs within the tumor microenvironment. The
activation of PRRs by tumor-related signals, in many cases, leads
to the release of pro-inflammatory cytokines which can be benefi-
cial by leading to proper activation of antigen presenting cells and
subsequent T cell activation. However, it is well established that
chronic inflammation can play roles during all stages of tumorige-
nesis and can be associated with poor clinical prognosis,depending
on the type of pro-inflammatory cytokines and cancer (3–5). Here
we describe the current literature on the role of PRRs, with a special
focus on nucleotide-binding leucine-rich repeat (NLR) proteins,
in cancer and how they might be utilized in tumor immunotherapy
(summarized in Table 1).
The NLR family is comprised of over 22 members in humans
(18, 19). NLR proteins are characterized by the presence of
three homologous domains: a central nucleotide-binding and
oligomerization (NACHT) domain, a C-terminal leucine-rich
repeat domain (LRR), and an N-terminal effector domain (18,
19). As the name indicates, the NACHT domain is important for
oligomerization, the LRR domain is important for ligand sensing,
and the N-terminal effector domain recruits downstream signaling
molecules (20, 21).
Within the NLR family, NLRP1, NLRP3, and NLRC4, as well
as the PYHIN family member Absent in Melanoma 2 (AIM2),
have been shown to form large multi-protein complexes termed
inflammasomes. There is evidence that NLRP6 may also form
a functional inflammasome (9); however, additional studies are
required to confirm this. Inflammasomes are composed of an
NLR protein (or AIM2), an adaptor protein apoptosis-associated
speck-like protein containing a Card domain (ASC), and the
cysteine protease caspase-1. Inflammasome activation is a two-
step process requiring a priming step and an assembly step.
The priming step results in the transcription of pro-IL-1β and
pro-IL-18 along with certain inflammasome components (22,
23). The second step, which can be triggered by a variety of
stimuli, results in the assembly and activation of inflamma-
somes. Inflammasome activation leads to the cleavage of pro-
caspase-1 and its subsequent activation, which in turn cleaves
pro-IL-1β and pro-IL-18 into their mature forms that can be
secreted from the cell. Additionally, caspase-1 activation can lead
to an inflammatory form of cell death known as pyroptosis
(18, 23).
In addition, there are also reports of non-canonical inflam-
masome activation independent of caspase-1. For example, the
receptor dectin-1 activates caspase-8 leading to processing and
secretion of IL-1β upon sensing fungi or mycobacteria (24). Non-
canonical inflammasome activation of caspase-11 has also been
shown to be important for IL-1β secretion, caspase-1 activation,
and macrophage cell death in response to Escherichia coli, Citrobac-
ter rodentium, and Vibrio cholera (25). These data demonstrate
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Table 1 | Role of NLRs in cancer.
NLR Type of cancer Possible mechanism Reference
NLRC4 Plays a protective role in mouse models of
colitis-associated colorectal cancer (CAC)
NLRC4 may regulate apoptosis in colonic epithelial cells Hu et al. (6), and Sadasivam et al. (7),
and Hu et al. (8)
NLRP6 Plays a protective role in CAC Absence of NLRP6 leads to an increase in Prevotellaceae
in the intestines and increased inflammation
Elinav et al. (9), Hu et al. (10), Normand
et al. (11), and Chen et al. (12)
NLRP3 Plays a protective role in CAC NLRP3 drives secretion of IL-18 which leads to activation
of STAT1 and tumor suppression
Allen et al. (13) and Zaki et al. (14)
Promotes tumor formation in a mouse
model of fibrosarcoma
Presence of NLRP3 leads to an decrease in NK cells and
CD11b+Gr-1int myeloid cells leading to increased
tumorigenesis
Chow et al. (15)
Promotes pulmonary metastasis in
intravenous B16F10 and RM-1 prostate
mouse models
NLRP12 Plays a protective role in CAC Absence of NLRP12 leads to dysregulation of canonical
or non-canonical NF-κB signaling leading to increased
inflammation
Zaki et al. (16) and Allen et al. (17)
important roles of various other pathways in processing of IL-1β.
Importantly, non-canonical inflammasomes may also play a role
in cancer-related inflammation.
Within the past 10 years, cancer-related inflammation was
added to the list of cancer hallmarks (26, 27). Inflammation has
been linked to tumor initiation, progression, angiogenesis, metas-
tasis, tumor cell proliferation and survival, and alterations in the
anti-tumor adaptive immune response. Sources of tumor-related
inflammation include bacterial and viral infections, environmen-
tal irritants and obesity, and tumor-elicited or therapy-induced
inflammation. Pro-inflammatory cytokines, such as IL-1β and
IL-6, are critical mediators for inflammation-promoted tumori-
genic effects and play critical roles in tumorigenesis (3, 4, 26, 27).
For future development of therapeutic strategies, it will be cru-
cial to understand how NLRs and inflammasomes are activated
during tumor progression and how pro-inflammatory cytokines
downstream of their activation impact tumorigenesis.
NLRC4
NLRC4
The PRR NLRC4 contains an N-terminal caspase activation and
recruitment domain (CARD), a central NACHT domain, and a C-
terminal LRR as depicted in Figure 1A (28,29). The CARD domain
present in NLRC4 allows for direct interaction with pro-caspase-1
(28). However, optimal caspse-1 activation requires the adaptor
protein ASC (30–32). NLRC4 is classically understood to recog-
nize a number of Gram-negative bacteria including Salmonella
enterica, Anaplasma phagocytophilum, Pseudomonas aeruginosa,
and Legionella pneumophila, which in turn leads to subsequent
activation of the NLRC4 inflammasome (31, 33–35). More specif-
ically, cytosolic flagellin and proteins with structural homology to
flagellin such as PrgJ, a component of type III secretion systems,
have also been shown to activate the NLRC4 inflammasome (36–
38). The NLRC4 inflammasome works in concert with neuronal
apoptosis inhibitor protein (NAIP) 2 to recognize PrgJ-like pro-
teins and NAIP5 to recognize cytosolic flagellin (39–41). NAIP
proteins, like NLRC4, have a C-terminal LRR domain, a central
NACHT domain, and an N-terminal baculovirus IAP repeat (BIR)
instead of the CARD domain (42).
NLRC4 AND CANCER
NLRC4 along with caspase-1 has been shown to regulate tumori-
genesis in a mouse model of colitis-associated colorectal cancer
(CAC) (6). In this model, cancer was induced by administra-
tion of azoxymethane and dextran sodium sulfate (AOM-DSS)
to mice. Interestingly, Nlrc4−/− and caspase-1−/− mice exhibited
increased tumor formation compared to wild-type mice. How-
ever, this phenotype was specific to colorectal cancer and not DSS
colitis indicating that increased colonic inflammation was not the
driving force for the enhanced tumorigenesis seen in Nlrc4−/−
and caspase-1−/−mice and instead was likely due to a cell intrinsic
mechanism. Although a definitive mechanism was not determined
in the study, it is speculated that NLRC4 may be playing a role in
alterations in colonic epithelial cell apoptosis as p53 activation has
been linked to NLRC4 gene expression (7). Such a notion was fur-
ther supported by the generation of wild-type and Nlrc4−/− bone
marrow chimeras. Nlrc4−/− mice receiving a wild-type bone mar-
row transplant had similar tumor loads as Nlrc4−/−mice receiving
Nlrc4−/− bone marrow in the CAC model, but exhibited signifi-
cantly higher tumor burdens than wild-type mice receiving either
wild-type or Nlrc4−/− bone marrow (8). This observation indi-
cates that NLRC4 plays a CAC-suppressive role confined to cells
other than in the hematopoietic compartment.
An alternative hypothesis that has been proposed involves the
role of NLRC4 in the regulation of commensal microbiota. NLRC4
is important for detecting bacterial pathogens in the intestines
without becoming activated by the presence of commensal organ-
isms (44). Interestingly, Nlrc4−/− mice have alterations in their
microflora compared to wild-type mice (9), indicating that NLRC4
is in some way important for the regulation of intestinal micro-
biota. The differences in microbiota seen in Nlrc4−/− mice did
not lead to enhanced susceptibility to DSS-induced colitis (9). In
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FIGURE 1 | (A) Structure of the NLRC4 inflammasome and NAIP
proteins. (B) Summary of immunotherapy utilizing activation of
NLRC4 (43). EL4 thymoma cells were transduced to express flagellin
from S. typhimurium. Mice were then immunized with irradiated EL4
cells expressing flagellin. Flagellin is recognized by TLR5 and NLRC4
in the presence of tumor antigens leading to production of
pro-inflammatory cytokines and an enhanced anti-tumor CD8+ T cell
response.
concert with these data Nlrc4−/− mice co-housed with wild-type
mice, which leads to transmission of the intestinal microbiota,
exhibited no differences in CAC tumorigenesis (10). Therefore
indicating that alterations in the microbiota in the absence of
NLRC4 are not correlated with progression of CAC.
NLRC4 AND TUMOR IMMUNOTHERAPY
Activation of NLRC4 results in the potent secretion of pro-
inflammatory cytokines necessary for priming an effective adap-
tive immune response. Priming an immune response is especially
problematic in a tumor environment where antigens are altered
or are simply overexpressed self-antigens and the immune milieu
is generally suppressive (45). A novel set of experiments were per-
formed integrating the activation of TLR5, NAIP5, and NLRC4
by bacterial flagellin into tumor immunotherapy (43). In these
studies, B16 melanoma cells and EL4 thymoma cells expressing
flagellin from Salmonella typhimurium were generated. Both EL4
and B16 cells expressing flagellin were unable to establish tumors
in vivo. In addition, EL4 and B16 cells expressing flagellin also
induced a potent anti-tumor response from CD4 and CD8 T cells.
Immunization of mice with irradiated EL4 cells expressing fla-
gellin protected mice during subsequent challenge with live EL4
cells (Figure 1B). These data indicate that activation of TLR5,
NAIP5, and NLRC4 during therapeutic strategies including tumor
cell vaccination could be beneficial.
NLRP6
NLRP6
The structure of NLRP6 is comprised of an N-terminal Pyrin
domain, a central NACHT domain and a C-terminal LRR as seen
in Figure 2A (46). It is unclear if NLRP6 is able to form a functional
inflammasome like NLRP1, NLRP3, NLRC4, or AIM2. From over-
expression studies in human embryonic kidney (HEK) 293T cells,
NLRP6 was recruited to ASC speck-like structures. In addition,
COS-7L cells co-transfected with plasmids encoding pro-caspase-
1, ASC, and NLRP6 were shown to secrete IL-1β (46). Additionally,
in vivo studies suggest that NLRP6 may be forming an inflamma-
some (9). However, whether NLRP6 is able to be recruited to an
inflammasome complex and cleave IL-1β when expressed at basal
levels has not been determined.
NLRP6 has no identified ligand; however, it was recently shown
to play a significant role as a negative regulator of inflamma-
tory signaling during bacterial infection (47). Nlrp6−/− mice
had decreased mortality and bacterial burdens when challenged
with Listeria monocytogenes and S. typhimurium, accompanied by
increased neutrophil influx. Additionally, Nlrp6−/− macrophages
had increased NF-κB and ERK activation in response to bacterial
infection. These data highlight NLRP6 as a negative regulator of
inflammation with a role to potentially dampen pathology and
damage to the host.
NLRP6 AND CANCER
NLRP6 is highly expressed in the duodenum, ileum, and colon,
which prompted studies to determine the role of NLRP6 in the
intestine (11). Like NLRC4, NLRP6 was shown to negatively reg-
ulate colitis and CAC in mice (9–12). In the AOM-DSS CAC
model, Nlrp6−/− mice had increased pathology and tumor num-
bers compared to wild-type mice. Nlrp6−/− colons exhibited
increased expression of pro-inflammatory cytokines indicating an
inability of mice to control inflammation within the intestine.
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FIGURE 2 | (A) Structure of NLRP6. (B) NLRP6 is important for
controlling the growth of Prevotella in the intestines of mice (9).
Interactions between intestinal epithelial cells and pathogenic species of
microbiota will lead to epithelial cell damage. Factors secreted from
damaged epithelial cells activate NLRP6. Activation of NLRP6 leads to
processing and secretion of IL-18 and a decrease in Prevotella. The
presence of Prevotella is correlated with colitis and colorectal cancer in
humans.
Moreover, Nlrp6−/− mice exhibited an increased level of epithe-
lial proliferation and a decreased ability to heal wounds (11,
12). These data demonstrate a unique role for NLRP6 in con-
trolling intestinal inflammation, preserving the integrity of the
intestinal epithelial barrier, and wound healing in the intestine.
Without NLRP6, the intestine is more susceptible to epithelial
damage, which in turn increases inflammation and susceptibility
to CAC.
In other studies focusing on the role of NLRP6 and colitis,
Nlrp6−/− mice were shown to have significantly altered intestinal
microbiota (9). Of note, Nlrp6−/−mice had an increase in the phy-
lum Bacteroidetes family Prevotellaceae as described in Figure 2B.
The increased inflammation and colitis seen in Nlrp6−/− mice
was attributed to the presence of Prevotellaceae, and these colitis-
conferring bacteria could be transmitted to co-housed wild-type
mice leading to enhanced disease. The role of Prevotellaceae was
not examined in the mouse model of CAC. However, wild-type
mice co-housed with Nlrp6−/− mice exhibit similar tumor score
indicating that the microbiota present in Nlrp6−/−mice promotes
enhanced CAC (10). In addition, due to the increased inflamma-
tion present in the intestine colonized with Prevotellaceae, it could
be hypothesized that the presence of Prevotellaceae might lead to
an increased susceptibility to colorectal cancer. Interestingly, Pre-
votellaceae was also shown to be prominent in the microbiota of
patients with inflammatory bowel disease and was significantly
increased in colorectal cancer patients (48–50), thus providing a
link between Prevotellaceae and colorectal cancer. However, it is
unknown whether the increased inflammation due to presence of
Prevotellaceae leads to inflammatory bowel disease and subsequent
increased risk for colorectal cancer, or if Prevotellaceae can directly
increase the risk for colorectal cancer independent of inflamma-
tory bowel disease. Additional studies need to be performed to
clarify the role of Prevotellaceae in the development of colorectal
cancer.
NLRP6 AND TUMOR IMMUNOTHERAPY
Although there is no described tumor immunotherapy directly
involving NLRP6, this area of research represents an interesting
potential. As mentioned above, NLRP6 is a negative regulator of
inflammation during bacterial infections. However, the role of
NLRP6 as a negative regulator of sterile inflammation has not
been explored. Chronic inflammation plays a crucial role in the
initiation and progression of cancer (3, 4). If NLRP6 has a more
global role in suppressing inflammation, it is possible that NLRP6
may be important in dampening tumor-promoting inflammation.
Alternatively, inflammation is important for activating dendritic
cells for proper antigen presentation and T cell activation (45).
NLRP6 has the potential to alleviate inflammation that is crucial
for an effective T cell response. Further studies of NLRP6 will need
to be pursued to determine if it contributes to tumor progression
or protection.
Alterations in microbiota have been shown to impact the sever-
ity of inflammatory bowel disease and colorectal cancer in humans
and mice (48–50). The microbiota is very pliable making it an
ideal therapeutic target. With the development of probiotics, fecal
transplants, and antibiotic treatments, there are a number of
ways to treat dysbiosis in the intestine. Preventative treatments
to alter the microbiota of patients with inflammatory bowel dis-
ease or dysbiosis may decrease levels of inflammation present in
the intestine, thereby decreasing the risk of developing colorec-
tal cancer. Moreover, treatment of dysbiosis in colorectal cancer
patients may alleviate symptoms. Future studies should include
determining if mutations in NLRP6 are correlated with colorec-
tal cancer and dysbiosis in humans, specifically with the increased
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Prevotellaceae. If a correlation exists between NLRP6 and colorec-
tal cancer in humans, NLRP6 may serve as a valuable biomarker
and therapeutic target.
NLRP3
NLRP3
NLRP3 contains an N-terminal Pyrin domain, a NACHT domain,
and a C-terminal LRR as seen in Figure 3A (18). NLRP3 is
expressed by a number of cells including epithelial cells, neu-
trophils, macrophages, and dendritic cells (51, 52). Upon activa-
tion, NLRP3 forms a complex with ASC, and caspase-1 leading to
pyroptosis and the release of inflammatory cytokines. A number of
stimuli are able to activate the NLRP3 inflammasome. Pathogens
including Candida albicans, Staphylococcus aureus, and Influenza,
among others, have been shown to activate the NLRP3 inflamma-
some (53–55). Additionally, host-derived stress or danger signals
are able to activate the NLRP3 inflammasome, including extracel-
lular ATP and monosodium urate crystals (55–57). Exposure to
environmental irritants including silica and asbestos will also lead
to activation of the NLRP3 inflammasome (58–60). It is hypoth-
esized that the numerous diverse NLRP3 agonists converge on a
common pathway that results in NLRP3 inflammasome activation.
Currently, potassium and calcium fluxes along with the generation
of reactive oxygen species (ROS) and mitochondrial dysfunction
have all been shown to be required for NLRP3 inflammasome
activation (61–65).
Cancer cells also exhibit altered metabolic activity in order
to support increased proliferation and survival, and can some-
times display increased ROS production (68, 69). Thus, it could
be hypothesized that dysfunctional mitochondria in cancer cells
activate the NLRP3 inflammasome, leading to an increase in
tumor-promoting pro-inflammatory cytokines. NLRP3 activation
by mitochondria-associated factors from cancer cells is not well
studied and is an area that warrants further investigation.
NLRP3 AND CANCER
NLRP3, like NLRC4 and NLRP6, is important for prevention of
CAC development in the AOM-DSS model (13, 14). Nlrp3−/−
mice had increased polyp numbers and size and worsened pathol-
ogy compared to wild-type mice. This phenotype was also seen in
Asc−/− and caspase-1−/− mice, indicating that the NLRP3 inflam-
masome is important in suppressing CAC development. Impor-
tantly, it was shown that the presence of NLRP3 in hematopoi-
etic cells was necessary for this the tumor-suppressing effect in
response to AOM-DSS challenge (13). Furthermore, IL-18 lev-
els were dramatically reduced in the colon of Nlrp3−/− and
FIGURE 3 | (A) Structure of the NLRP3 inflammasome. (B) Cancer therapies
activating the NLRP3 inflammasome have opposing roles. Treatment with the
chemotherapeutic drug oxaliplatin leads to the release of ATP from dying
cancer cells. ATP interacts with the P2X7 receptor on dendritic cells leading to
activation of the NLRP3 inflammasome. IL-1β secreted by dendritic cells
primes anti-tumor CD8+ T cells and promotes the anti-tumor response (66). In
contrast, gemcitabine (Gem) and 5-fluorouracil (5FU) activate the NLRP3
inflammasome via release of cathepsin B in myeloid derived suppressor cells
leading to IL-1β secretion. IL-1β promotes CD4+ T cells to secrete the cytokine
IL-17, which blunts the anti-tumor response (67).
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caspase-1−/− mice. Treatment of caspase-1−/− mice with recom-
binant IL-18 led to a reduction in disease demonstrating a crucial
role of IL-18 in protection against CAC development (14). Par-
tial amelioration of disease in caspase-1−/− by administration of
exogenous IL-18 was also demonstrated in a separate study (70).
In concert with these data, Myd88−/−, Il18−/−, and Il18r−/− mice
were also shown to be more susceptible to DSS-induced colitis and
colon cancer (71).
IL-18 was proposed to have a role in IFN-γ mediated activation
of STAT1, which is known to have a role in tumor suppression (72).
These data imply that the absence of NLRP3 results in decreased
IL-18 production and STAT1 signaling that are necessary for pro-
tection against CAC potentially by playing a role in epithelial
repair. Treatment with recombinant IL-18 did not fully alleviate
symptoms indicating that some other mechanisms may be at play.
It should be noted that in another study utilizing the AOM-DSS
model, Nlrp3−/− mice exhibited a similar tumor load as WT mice
(6). The difference in phenotypes may be attributed to alterations
in mouse intestinal microbiota or differences in experimental pro-
cedures. However, whether NLRP3 is important for protection in
colitis-associated cancer still remains unclear.
In contrast to the protective role of NLRP3 in CAC, NLRP3
was shown to promote tumor formation in a chemical-induced
fibrosarcoma model (15). Nlrp3−/− mice treated with methyl-
cholanthrene (MCA) exhibited prolonged tumor-free survival
compared to wild-type mice. In concert with this data, Nlrp3−/−
mice challenged intravenously with B16F10 melanoma and RM-1
prostate carcinoma cells had significantly fewer metastasis com-
pared to wild-type mice. Reduced pulmonary metastasis was also
seen in Nlrp3−/− mice using orthotopic transplant of E0771
mammary adenocarcinoma cells (15). The decrease in tumor for-
mation was attributed to an increase in natural killer (NK) cells
and CD11b+Gr-1int myeloid cells seen in Nlrp3−/− mice. The
CD11b+Gr-1int myeloid cells secreted CCL5 and CXCL9 that were
important for recruiting NK cells into the tumor microenviron-
ment (15), demonstrating a role for NLRP3 in the suppression
of NK cell activation and promotion of a suppressive tumor
environment.
In an interesting in vitro study of late stage metastatic
melanoma cell lines, HS294T and 1205Lu cells were shown to
constitutively produce IL-1β in culture (73). In contrast, non-
metastatic melanoma cell lines secreted less or no IL-1β. HS294T
and 1205Lu cells also expressed NLRP3, ASC, and caspase-1 and
secreted factors that resulted in increased macrophage chemotaxis
and angiogenesis (73). These data merit further study on the role
of inflammasome activation in metastatic tumor cells, and how
inflammasome activation is altered in tumor cells as they progress
from non-metastatic cells to ones with metastatic capacity.
NLRP3 AND IMMUNOTHERAPY
As inflammation has been shown to be both beneficial and
detrimental for cancer, it is fitting that NLRP3 activation
in immunotherapy can also be beneficial and detrimental.
Chemotherapy-induced cell death was shown to result in both
priming and activation of the NLRP3 inflammasome. Priming
occurred through TLR4 by high mobility group box-1 (HMGB1)
protein; ATP released from dying cells then lead to activation of the
NLRP3 inflammasome (66). NLRP3 activation in dendritic cells by
oxaliplatin-treated tumor cells resulted in the release of IL-1β that
was critical for priming of anti-tumor CD8+ T cells as depicted
in Figure 3B. This knowledge is useful in formulating a therapeu-
tic setting where chemotherapeutic drugs known to activate the
NLRP3 inflammasome may be used to improve prognosis.
In contrast, the chemotherapeutic agents gemcitabine (Gem)
and 5-fluorouracil (5FU), which have been shown to deplete
myeloid derived suppressor cells (MDSCs), activated NLRP3 in
MDSCs resulting in a diminished anti-tumor response (67, 74, 75).
Treatment with Gem or 5FU resulted in the release of cathepsin
B that was shown to activate NLRP3 with the subsequent secre-
tion of IL-1β. IL-1β then led to an enhanced IL-17 production
by CD4+ T cells as depicted in Figure 3B. Interestingly, treat-
ment of Il17a−/− mice with 5FU resulted in decreased tumor
size (67). Taken together these findings demonstrate a role for
NLRP3 activation in skewing a Th17 response and leading to a
decreased anti-tumor response. It should be noted that 5FU treat-
ment combined with IL-1R-blocking antibody lead to decreased
tumor size. Although treatment with IL-17-blocking antibodies
was not included in this study, combining IL-1R or IL-17 blocking
antibodies with chemotherapeutic treatment may lead to a better
outcome for some patients.
Another cancer immunotherapy is the use of dendritic cell vac-
cinations. Interestingly, the presence of NLRP3 led to a decrease
in survival during B16F10 melanoma challenge and subsequent
vaccination with B16-pulsed dendritic cells (76). The decrease
in vaccine efficacy was due to a significant increase in tumor-
infiltrating MDSCs and a decrease in CD8+ effector T cells. How
NLRP3 recruits MDSCs into the tumor environment is unknown.
MDSCs are very potent immunosuppressive cells that are associ-
ated with increased tumor growth (77). Determining the role that
NLRP3, or other NLRs, may play in MDSC recruitment will be an
important area of research to explore.
NLRP12
NLRP12
NLRP12, also known as Monarch-1, is composed of an N-terminal
Pyrin domain, an NACHT domain, and a C-terminal LRR (78) as
shown in Figure 4A. NLRP12 was shown to associate with ASC
in an overexpression system; however, whether NLRP12 forms a
functional inflammasome has not been well documented (79).
NLRP12 is highly expressed in granulocytes in the bone marrow,
and also macrophages in the spleen (80). Currently, NLRP12 is
viewed as a regulator of inflammation. However, NLRP12 has been
shown to have opposing roles in activation of NF-κB. Transient
transfection of 293T cells with NLRP12 and ASC constructs led
to transcription of an NF-κB luciferase reporter, demonstrating a
role for NLRP12 in the activation of NF-κB (79). NLRP12 seems to
inhibit the non-canonical NF-κB activation in the human mono-
cytic cell line THP-1 by the binding of NLRP12 to NF-κB inducing
kinase (NIK) and leading to the degradation of NIK (81). Interest-
ingly, in humans, mutations in NLRP12 have been associated with
a periodic fever syndrome (82, 83). When HEK293T cells were
transfected with NLRP12 constructs harboring these mutations,
an increase of NF-κB activation was seen (82). Missense muta-
tions in NLRP12 in periodic fever syndrome were also associated
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FIGURE 4 | (A) Structure of NLRP12. (B) When NLRP12 is present in
intestinal epithelial cells it interacts with TRAF3 leading to stabilization of
TRAF3 levels. Stabilization of TRAF3 leads to regulation of the non-canonical
NF-κB pathway and diminished levels of the chemokines CXCL12 and
CXCL13, both of which are upregulated in human cancers. Regulation of
the non-canonical NF-κB pathway by NLRP12 leads to decreased
inflammation and tumorigenesis in the colon (17).
with increased caspase-1 activation and had no effect on NF-κB
(83, 84). These data further demonstrate NLRP12 as a potential
negative regulator of inflammation and imply that NLRP12 may
play a causal role in certain human disease.
NLRP12 has also been implicated in the control of bacterial
pathogens. Both NLRP12 and IL-18 were shown to be crucial
for control of Yersinia pestis infection (85), but NLRP12 was
dispensable during infections with Klebsiella pneumoniae and
Mycobacterium tuberculosis (80).
NLRP12 AND CANCER
The role of NLRs in colorectal cancer is well studied. NLRP12,
like NLRP3, NLRP6, and NLRC4, plays a protective role during
colorectal tumorigenesis. Nlrp12−/− mice exhibited an increase
in tumor numbers in the AOM-DSS CAC model. Addition-
ally, colons from Nlrp12−/− mice had increased tissue damage,
pro-inflammatory cytokine production, and ERK, STAT3, and
NF-κB activation (16). The increased tumorigenesis was attrib-
uted to a lack of NLRP12 in hematopoietic cells. Bone marrow-
derived macrophages from Nlrp12−/− mice exhibited an increase
in phosphorylation of p105/NF-κB1 in response to lipopolysac-
charide stimulation demonstrating a role for NLRP12 in regula-
tion of the canonical NF-κB pathway (16). It was hypothesized
that dysregulation of the canonical NF-κB signaling in Nlrp12-
deficient hematopoietic cells leads to increased inflammation and
tumorigenesis.
In a more recent study, NLRP12 expression in non-
hematopoietic cells was shown to play a protective role in CAC
(17). Nlrp12−/− mice exhibited increased inflammation and
tumor numbers. Interestingly, both in vitro and in vivo NLRP12
deficiency resulted in an increased activation of the non-canonical
NF-κB pathway. Nlrp12−/− mice expressed elevated levels of
CXCL12 and CXCL13, and also increased phosphorylation of
ERK (17). It was hypothesized that NLRP12 negatively regulates
non-canonical NF-κB signaling via interactions with NIK and
TRAF3. In the absence of NLRP12, there is an increased level of
inflammation and cancer-promoting chemokines as depicted in
Figure 4B. Discrepancies seen in canonical versus non-canonical
NF-κB signaling in vitro may be due to the nature of the stimu-
lus used. NLRP12 was shown to downregulate canonical NF-κB
signaling in response to stimulation with TLR agonists whereas,
in response to stimulation with TNF-α or CD40L, NLRP12 regu-
lates non-canonical NF-κB signaling. These data suggest NLRP12
may modulate both canonical and non-canonical NF-κB signaling
depending on the upstream stimuli.
It is possible that a common pathway exists which NLRs con-
verge on leading to protection against colorectal cancer. This likely
includes maintenance of epithelial barrier integrity. Inflamma-
tion, as a result of altered pro-inflammatory signaling or altered
microbiota, leads to the breakdown of the epithelial barrier in the
intestine. When the barrier between immune cells and the micro-
biota dissolves, PRR ligands are in abundance and activate cells in
the intestine, leading to the release of more pro-inflammatory
cytokines and creating a cycle of inflammation that leads to
development and progression of cancer.
NLRP12 AND IMMUNOTHERAPY
The possibility of targeting NLRP12 as a therapeutic treatment
has not been explored. NLRP12 is crucial for the down-regulation
of NF-κB signaling. Activation of NF-κB has been correlated with
enhanced tumor cell survival and growth (86). As NLRP12 is a
regulator of NF-κB, it would be beneficial to determine the role
of NLRP12 in human cancer. Additionally, it may serve as a more
specific target in immunotherapy compared to NF-κB.
INTERLEUKIN-1β
IL-1β AND CANCER
As mentioned above, inflammasome activation leads to the pro-
cessing and secretion of IL-1β. IL-1β is a potent pro-inflammatory
cytokine associated with tumor growth and angiogenesis (87). In
a study utilizing a B16 melanoma model, IL-1β-deficient mice had
remarkably reduced subcutaneous tumor size and lung metas-
tasis compared to wild-type mice. Additionally, IL-1β-deficient
mice and wild-type mice treated with an IL-1R blocking antibody
had significantly reduced angiogenesis as measured by microves-
sel density compared to wild-type mice (88). In concert with
these data, IL-1β- and IL-1α-deficient mice had decreased tumor
numbers and tumor size in the MCA model of fibrosarcoma. Addi-
tionally, IL-1R antagonist (IL-1Ra)-deficient mice had increased
tumor size (89). Expression of IL-1βby tumor cells also contributes
to tumor growth and angiogenesis. Mice challenged with Lewis
lung carcinoma cells (LLC) transduced with human IL-1β exhib-
ited increased tumor size and vasculature compared to LLC cells
alone (90). These studies are critical in demonstrating a role for
IL-1β in promoting growth of solid tumors, angiogenesis, and
metastasis.
IL-1β AND IMMUNOTHERAPY
IL-1 expression is enhanced in a number of cancers including lung,
colon, melanoma, and breast (91, 92). Studies in mouse models
have demonstrated therapeutic promise for treatment with IL-1
blocking antibodies and also combining IL-1 blocking antibod-
ies with traditional anti-cancer immunotherapies (67, 87, 88).
www.frontiersin.org November 2013 | Volume 4 | Article 370 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Janowski et al. NLRs in carcinogenesis
Anakinra is an IL-1R antagonist that is used to treat a number of
autoinflammatory disorders (91). Anakinra in combination with
dexamethasone has shown promise in slowing myeloma prolifera-
tion in patients with smoldering myeloma (93). Due to the strong
correlation between IL-1β and tumor progression, it is worthwhile
to continue to explore Anakinra and other IL-1R antagonists as
tumor immunotherapy options.
INTERLEUKIN-18
IL-18 AND CANCER
Along with IL-1β, the cytokine IL-18 is also cleaved by caspase-1
into its mature form and plays both beneficial and detrimental
roles in the progression of cancer. In B16 melanoma models IL-
18 acts as both an immunosuppressive and prometastatic factor.
In an intravenous model of B16 melanoma IL-18 was shown to
upregulate PD-1 expression on NK cells. Knock-down of IL-18 led
to reduced pulmonary metastasis and increased NK cell function
(94). Other studies showed that administration of IL-18 binding
protein, which blocks IL-18, before injection of B16 melanoma
into the spleen reduced metastasis to the liver. Mechanistically it
was shown that treatment with IL-18 binding protein also reduced
adhesion of B16 melanoma cells to hepatic sinusoidal endothelial
cells leading to decreased metastasis (95). In concert with these
data, administration of exogenous IL-18 led to an increase of
adherent melanoma cells to sinusoidal endothelial cells (96). In
humans an increase in IL-18 is correlated with various types of
cancer including ovarian carcinoma, head and neck squamous
carcinoma, breast cancer, and others (97–100). These data clearly
demonstrate a pro-tumorigenic role of IL-18 both in humans and
mice. Additionally, IL-18 may serve as a valuable biomarker for
certain types of cancer.
In contrast, IL-18 plays a protective role during development
of AOM-DSS CAC as mentioned above. IL-18−/− and IL-18r−/−
mice were more susceptible to colon polyp formation and treat-
ment of caspase-1−/− mice with recombinant IL-18 leads to
amelioration of disease (14, 70, 71). It was also shown that admin-
istration of IL-18 induced anti-tumor immunity in mice bearing
B16 melanoma tumors expressing B7-1 (CD80). However admin-
istration of IL-18 to mice bearing B16 melanoma tumors alone
had no effect on tumorigenesis (101). Therefore the role of IL-18
may vary depending on the types of tumor and the therapies it is
combined with.
CONCLUSION
It is clear that NLRs possess roles far from just pathogen recogni-
tion. NLRs play crucial roles in both promoting and dampening
inflammation associated with tumors. Although the role of NLRs
is best characterized in colorectal cancer, NLRs likely play a role
in many other types of cancer. Further research needs to be per-
formed to determine what specifically in the tumor environment
leads to activation or down-regulation of NLRs. Danger signals
released from dying cells have been shown to activate the NLRP3
inflammasome and it is possible that cancer cells release spe-
cific ligands capable of activating other NLRs. As some NLRs,
like NLRP12, seem to be regulators of inflammation it could be
hypothesized that mutations in these genes could correlate with
tumor initiation and progression. A deeper understanding of the
role of NLRs in the stages of cancer from initiation to metastasis
will aid the development of new therapeutic strategies.
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